帕博利珠单抗或安慰剂联合化疗±贝伐珠单抗治疗持续性、复发性或转移性宫颈癌:KEYNOTE-826随机临床试验的亚组分析
KEYNOTE-826是一项全球3期随机双盲安慰剂对照试验的探索性亚组分析,纳入617例持续性、复发性或转移性宫颈癌患者。在CPS≥1人群和意向治疗人群中,帕博利珠单抗组在贝伐珠单抗使用与否、铂类选择、既往放化疗暴露及组织学类型各亚组的总生存风险比均倾向于帕博利珠单抗组,无进展生存亦在各亚组中延长。
要点
- CPS≥1人群中,帕博利珠单抗组总生存风险比在贝伐珠单抗使用与否、铂类选择、既往放化疗及组织学类型各亚组均倾向于帕博利珠单抗组。
- 意向治疗人群中,帕博利珠单抗组总生存风险比同样在各亚组中倾向于帕博利珠单抗组。
- 与总生存相似,帕博利珠单抗在CPS≥1和意向治疗人群的所有亚组中均延长无进展生存。
核心结论
- 该试验结果提示,在持续性、复发性或转移性宫颈癌患者中,化疗加用帕博利珠单抗(联合或不联合贝伐珠单抗)在各亚组中改善了总生存。
研究设计与样本
- 全球、3期、随机、双盲、安慰剂对照临床试验的探索性亚组分析,纳入617例未接受过系统化疗且不适合根治性治疗的持续性、复发性或转移性宫颈腺癌、腺鳞癌或鳞状细胞癌女性患者(中位年龄51岁,范围22-82岁)。
- 亚组分析于2018年11月20日至2021年5月3日进行。
- 干预为帕博利珠单抗200 mg每3周或安慰剂最多35个周期,联合化疗(紫杉醇175 mg/m2加顺铂50 mg/m2,或卡铂AUC 5)联合或不联合贝伐珠单抗15 mg/kg。
主要发现
- CPS≥1人群中,总生存风险比在以下亚组倾向于帕博利珠单抗组:使用贝伐珠单抗(HR 0.62;95%CI 0.45-0.87)与未使用贝伐珠单抗(HR 0.67;95%CI 0.47-0.96);使用卡铂(HR 0.65;95%CI 0.50-0.85)与使用顺铂(HR 0.53;95%CI 0.27-1.04);仅既往放化疗(HR 0.56;95%CI 0.39-0.81)与无仅既往放化疗(HR 0.72;95%CI 0.52-1.00);鳞癌(HR 0.60;95%CI 0.46-0.79)与非鳞癌(HR 0.70;95%CI 0.41-1.20)。
- 意向治疗人群中,总生存风险比在以下亚组倾向于帕博利珠单抗组:使用贝伐珠单抗(HR 0.63;95%CI 0.47-0.87)与未使用贝伐珠单抗(HR 0.74;95%CI 0.53-1.04);使用卡铂(HR 0.69;95%CI 0.54-0.89)与使用顺铂(HR 0.59;95%CI 0.32-1.09);仅既往放化疗(HR 0.64;95%CI 0.45-0.91)与无仅既往放化疗(HR 0.71;95%CI 0.53-0.97);鳞癌(HR 0.61;95%CI 0.47-0.80)与非鳞癌(HR 0.76;95%CI 0.47-1.23)。
- 与总生存相似,帕博利珠单抗在CPS≥1和意向治疗人群的所有亚组中均延长无进展生存。
关键数值与推荐
- CPS≥1人群中,使用贝伐珠单抗亚组总生存HR 0.62(95%CI 0.45-0.87),未使用贝伐珠单抗亚组HR 0.67(95%CI 0.47-0.96)。
- CPS≥1人群中,使用卡铂亚组总生存HR 0.65(95%CI 0.50-0.85),使用顺铂亚组HR 0.53(95%CI 0.27-1.04)。
- CPS≥1人群中,仅既往放化疗亚组总生存HR 0.56(95%CI 0.39-0.81),无仅既往放化疗亚组HR 0.72(95%CI 0.52-1.00)。
- CPS≥1人群中,鳞癌亚组总生存HR 0.60(95%CI 0.46-0.79),非鳞癌亚组HR 0.70(95%CI 0.41-1.20)。
- 意向治疗人群中,使用贝伐珠单抗亚组总生存HR 0.63(95%CI 0.47-0.87),未使用贝伐珠单抗亚组HR 0.74(95%CI 0.53-1.04);使用卡铂亚组HR 0.69(95%CI 0.54-0.89),使用顺铂亚组HR 0.59(95%CI 0.32-1.09);仅既往放化疗亚组HR 0.64(95%CI 0.45-0.91),无仅既往放化疗亚组HR 0.71(95%CI 0.53-0.97);鳞癌亚组HR 0.61(95%CI 0.47-0.80),非鳞癌亚组HR 0.76(95%CI 0.47-1.23)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown. OBJECTIVE: To assess efficacy outcomes in patient subgroups of KEYNOTE-826. DESIGN, SETTING, AND PARTICIPANTS: Exploratory subgroup analyses were conducted in a global, phase 3, randomized, double-blind, placebo-controlled clinical trial. Participants included women with persistent, recurrent, or metastatic adenocarcinoma, adenosquamous carcinoma, or squamous cell carcinoma of the cervix that had not been treated with systemic chemotherapy and was not amenable to curative treatment. This subanalysis was conducted from November 20, 2018, to May 3, 2021. INTERVENTIONS: Pembrolizumab, 200 mg, every 3 weeks or placebo for up to 35 cycles plus chemotherapy (paclitaxel, 175 mg/m2, plus cisplatin, 50 mg/m2, or carboplatin AUC 5 [area under the free carboplatin plasma concentration vs time curve]) with or without bevacizumab, 15 mg/kg. MAIN OUTCOMES AND MEASURES: Overall survival (OS) and progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1 in subgroups defined by use of bevacizumab (yes or no), choice of platinum (carboplatin or cisplatin), prior chemoradiotherapy (CRT) exposure only (yes or no), and histologic type (squamous or nonsquamous) in patients with programmed cell death ligand 1-positive tumors (defined as a combined positive score [CPS] ≥1) and in the intention-to-treat population. RESULTS: A total of 617 patients (median age, 51 years; range, 22-82 years) were enrolled in the trial. In the CPS greater than or equal to 1 population, hazard ratios (HRs) for OS favored the pembrolizumab group in all subgroups: with bevacizumab (HR, 0.62; 95% CI, 0.45-0.87) and without bevacizumab (HR, 0.67; 95% CI, 0.47-0.96), use of carboplatin (HR, 0.65; 95% CI, 0.50-0.85) and cisplatin (HR, 0.53; 95% CI, 0.27-1.04), with prior CRT only (HR, 0.56; 95% CI, 0.39-0.81) and without prior CRT only (HR, 0.72; 95% CI, 0.52-1.00), and squamous (HR, 0.60; 95% CI, 0.46-0.79) and nonsquamous (HR, 0.70; 95% CI, 0.41-1.20) histologic type. In the intention-to-treat population, HRs for OS also favored the pembrolizumab group in all subgroups: with bevacizumab (HR, 0.63; 95% CI, 0.47-0.87) and without bevacizumab (HR, 0.74; 95% CI, 0.53-1.04), use of carboplatin (HR, 0.69; 95% CI, 0.54-0.89) or cisplatin (HR, 0.59; 95% CI, 0.32-1.09), with prior CRT only (HR, 0.64; 95% CI, 0.45-0.91) and without prior CRT only (HR, 0.71; 95% CI, 0.53-0.97), and squamous (HR, 0.61; 95% CI, 0.47-0.80) and nonsquamous (HR, 0.76; 95% CI, 0.47-1.23) histologic type. Similar to OS, the addition of pembrolizumab prolonged PFS across all subgroups in the CPS greater than or equal to 1 and intention-to-treat populations. CONCLUSIONS AND RELEVANCE: The findings of this trial suggest that adding pembrolizumab to chemotherapy with or without bevacizumab improved OS across subgroups of patients with persistent, recurrent, or metastatic cervical cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03635567.
引用
- Tewari KS, Colombo N, Monk BJ, et al. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38095881. doi:10.1001/jamaoncol.2023.5410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。